Cargando…

Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets

Background: Targeted therapy for lung cancer with epidermal growth factor receptor (EGFR) mutations with tyrosine kinase inhibitors (TKIs) represents one of the major breakthroughs in lung cancer management. However, gradually developed resistance to these drugs prevents sustained clinical benefits...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Nan, Song, Yong'an, Zhang, Fan, Sun, Zhifu, Zhang, Xiaoju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456826/ https://www.ncbi.nlm.nih.gov/pubmed/32923394 http://dx.doi.org/10.3389/fonc.2020.01424

Ejemplares similares

LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in Non-small-Cell Lung Cancer
por: Xu, Tianwei, et al.
Publicado: (2020)

Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review
por: Zhou, Kexun, et al.
Publicado: (2023)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma
por: Yang, Hong, et al.
Publicado: (2021)

Comprehensive Profiling of lincRNAs in Lung Adenocarcinoma of Never Smokers Reveals Their Roles in Cancer Development and Prognosis
por: Li, Ying, et al.
Publicado: (2017)

ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review
por: Zeng, Zhu, et al.
Publicado: (2022)

Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion
por: Qin, Yanyan, et al.
Publicado: (2022)

Aggressive angiomyxoma of the pelvis and abdominal wall: Dramatic response to chemical ablation therapy
por: Li, Liu, et al.
Publicado: (2023)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer
por: Ye, Weilong, et al.
Publicado: (2022)

Integrated Multiomics Analyses Revealing Different Molecular Profiles Between Early- and Late-Stage Lung Adenocarcinoma
por: Yue, Dongsheng, et al.
Publicado: (2021)

Dramatic Response of an Aggressive Chest Wall Recurrence to Hyperthermia, Radiation, and Chemotherapy
por: Cohen, Justin, et al.
Publicado: (2017)

Dramatic Regression of a Fungating Breast Lesion Treated with Radiation Therapy
por: Gao, Robert W, et al.
Publicado: (2017)

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
por: Ni, Jie, et al.
Publicado: (2018)

Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
por: Xu, Chuncao, et al.
Publicado: (2021)

LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer
por: Dai, Jiali, et al.
Publicado: (2023)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Efficacy of Gefitinib and Methorexate in Patients With Advanced Stage and Recurrent Head and Neck Cancer
por: Irshad, Razia, et al.
Publicado: (2021)

Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
por: Arias Ron, David, et al.
Publicado: (2019)

Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review
por: Tian, Jiangfang, et al.
Publicado: (2022)

Dramatic Response of a Large Sacral Chordoma to Intensity Modulated Proton Beam Therapy
por: Schneider, Craig, et al.
Publicado: (2017)

Editorial: Primary and acquired resistance in lung cancer
por: Bruno, Rossella, et al.
Publicado: (2023)

Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial–Mesenchymal Transition by Aloe-Emodin Via PI3K/Akt/TWIS1 Signal Blockage
por: Peng, Minghui, et al.
Publicado: (2022)

Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence
por: Tulalamba, Warut, et al.
Publicado: (2023)

Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion
por: Ma, Qing, et al.
Publicado: (2022)

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib
por: Song, Xiang, et al.
Publicado: (2020)

The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells
por: de Almeida, Luciana Yamamoto, et al.
Publicado: (2021)

Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report
por: Kok, Victor C., et al.
Publicado: (2021)

Dramatic Regression of Presumed Acquired Retinal Astrocytoma with Photodynamic Therapy
por: Tuncer, Samuray, et al.
Publicado: (2014)

Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
por: Hong, Se Hyang, et al.
Publicado: (2020)

Heterogenous profiles between primary lung cancers and paired brain metastases reveal tumor evolution
por: Chen, Yanming, et al.
Publicado: (2023)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
por: Kim, Hyojeong, et al.
Publicado: (2013)

FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
por: Sun, Cuilan, et al.
Publicado: (2020)

miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
por: Ge, Peng, et al.
Publicado: (2019)

Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations
por: Xiu, Weigang, et al.
Publicado: (2021)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020)

A Dramatic Response to Toripalimab With Chemotherapy and Antiangiogenic Agent Followed by Surgery in a Stage IIIB Lung Adenocarcinoma Patient With an Uncommon EGFR Mutation: A Case Report
por: Zhai, Pengda, et al.
Publicado: (2022)

Integrated Analysis of the Transcriptome Profile Reveals the Potential Roles Played by Long Noncoding RNAs in Immunotherapy for Sarcoma
por: Pang, Boran, et al.
Publicado: (2021)

Transcriptome Analysis Reveals the Immune Infiltration Profiles in Cervical Cancer and Identifies KRT23 as an Immunotherapeutic Target
por: Li, Xia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oq35eci4mq0mdi3qpbpq0niqf2